Great candidates
- Adults with BMI 30+ or 27+ with a weight-related condition
- Patients who have plateaued on Semaglutide
- Insulin-resistant patients or those with prediabetes
- Those seeking accelerated results with medical supervision
Tirzepatide
Dual-pathway therapy for meaningful, lasting weight loss.
Compounded Tirzepatide — the same active ingredient as Mounjaro and Zepbound — activates two metabolic receptors at once. The result: greater satiety, faster fat loss, and stronger long-term outcomes.
What It Is
A dual incretin agonist.
Tirzepatide is the first medication to activate both GLP-1 and GIP receptors — two hormones your body already makes to regulate appetite and blood sugar. It doesn't override your biology. It restores it.
Approved by the FDA for type 2 diabetes (as Mounjaro) and chronic weight management (as Zepbound), tirzepatide has become the most-studied and most-effective weight loss medication on the market.
In the pivotal SURMOUNT-1 trial, patients on the highest dose lost an average of 22.5% of their total body weight over 72 weeks — a magnitude previously only achievable through bariatric surgery.
Compounded tirzepatide gives patients access to the same active ingredient — under a physician's care, without the shortages, denials, and cost barriers of brand-name Rx.
How It Works
Two pathways. One profound effect.
GLP-1 Receptor Agonism
Slows gastric emptying, curbs appetite, and improves insulin response — the same pathway as Semaglutide.
GIP Receptor Agonism
A second incretin pathway that amplifies fat metabolism and metabolic efficiency, unique to Tirzepatide.
Compounded Effect
Two mechanisms working in concert — clinical trials show significantly greater weight loss than GLP-1 alone.
Benefits
Why patients choose Tirzepatide.
Up to 22% Weight Loss
Highest average total body weight reduction of any FDA-approved weight loss medication.
Metabolic Overhaul
Significant improvements in A1C, blood pressure, LDL, triglycerides, and inflammation.
Powerful Appetite Control
Patients often describe an unmatched reduction in cravings and 'food noise' compared to other GLP-1s.
Faster Momentum
Many patients notice results within the first two weeks of dosing.
Is It Right For You?
Candidate criteria.
A licensed physician reviews every screening. These are general guidelines — your eligibility depends on the full picture of your health.
Requires physician review
- Personal or family history of medullary thyroid cancer
- Multiple endocrine neoplasia type 2 (MEN2)
- Active pancreatitis or gallbladder disease
- Pregnancy, planning pregnancy, or breastfeeding
Your Timeline
Physician-guided dose titration.
We start low and go slow — the safest, most effective way to reach your optimal dose.
- 01
Week 1 – 4
2.5 mg
Starting dose. Body acclimates; appetite noticeably reduced.
- 02
Week 5 – 8
5 mg
First titration. Steady weight loss and stronger satiety.
- 03
Week 9 – 12
7.5 mg
Increased efficacy; labs and coaching adjustments.
- 04
Month 4+
10 – 15 mg
Physician-guided titration to your optimal dose and maintenance.
Lifestyle Integration
Medication opens the door. You walk through it.
Every Tirzepatide protocol includes protein-forward nutrition guidance, strength-based movement coaching, and weekly touchpoints with our team. That's how patients keep the weight off long after the dose ends.
Explore GLP-1 & Weight LossFAQ
About Tirzepatide.
The most common questions from patients considering dual-pathway therapy.
Semaglutide activates only the GLP-1 receptor. Tirzepatide activates both GLP-1 and GIP receptors, producing a compounded effect on appetite, glucose control, and fat metabolism. Clinical trials show significantly greater weight loss with Tirzepatide.
The active ingredient (tirzepatide) is identical. Our formulations are compounded at licensed U.S. pharmacies under physician oversight — accessible, affordable, and without insurance requirements.
Clinical data shows an average of 15–22% total body weight reduction over 72 weeks. Individual results depend on dose, adherence, nutrition, and activity — all of which we support directly.
Mild GI symptoms (nausea, constipation, indigestion) are most common in the first 2 weeks. We titrate slowly and coach you through them. Serious side effects are rare and reviewed at every check-in.
A once-weekly subcutaneous injection — most patients self-inject in under a minute using a preloaded syringe or pen.
Many patients who plateau on Semaglutide see renewed progress on Tirzepatide because it engages a second metabolic pathway. Our physicians can transition you safely.
Keep reading
Related GLP-1 reading
Every article in the GLP-1 pillar answers a different question — the biology, the medications, the trade-offs and the real cost.
Semaglutide Explained
How the single-pathway GLP-1 works, what STEP-1 measured, and who it suits best.
Read The Article
Semaglutide vs Tirzepatide
An honest side-by-side on results, tolerability, dosing and cost.
Read The Article
Cost & Pricing
What GLP-1 therapy actually costs, what is included, and why compounded pricing differs.
Read The ArticleReady?
See if Tirzepatide is right for your body.
Explore the physician-guided GLP-1 & Weight Loss Program, or talk it through with our team first.